Free Trial
OTCMKTS:BIOQ

Bioqual Q4 2026 Earnings Results & Report

Bioqual logo
$31.00 0.00 (0.00%)
As of 11/12/2026

Bioqual reported Q4 2026 earnings on September 21, 2026. The company reported EPS of -$2.81, while revenue was $9.27 million.

Earnings Announcement Details

Quarter
Q4 2026
Time
Before Market Opens

Bioqual EPS Results

Actual EPS
-$2.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$9.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioqual Q4 2026 Earnings FAQ

Bioqual (OTCMKTS:BIOQ) reported earnings of -$2.81 per share for Q4 2026. The report was announced on Monday, September 21, 2026.

Bioqual reported revenue of $9.27 million for Q4 2026.

Bioqual Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
BIOQUAL Presents Financial Results for Fiscal Year 2026
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a biomedical research and contract research organization based in the United States. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations developing medical treatments, vaccines, and diagnostics.

Its activities include animal-model research, pharmacology, toxicology, infectious-disease studies, and vaccine and therapeutic efficacy testing. Bioqual has experience conducting research involving nonhuman primates and other laboratory animals, supporting the evaluation of potential products before they advance to human clinical trials.

The company’s services are designed to help clients assess safety, effectiveness, and biological responses across a range of medical and public-health applications. Publicly available information about Bioqual’s current leadership, geographic reach, and additional operating details is limited.

View Bioqual Profile